No more compromise between speed and sensitivity

Tumor-informed detection is the gold standard for MRD assay developers. However, maximizing performance has historically required selecting between amplicon and hybrid capture-based technologies, forcing a frustrating choice between turnaround time and sensitivity.

 

Now, you don’t have to choose. MRD Express cuts 7-day production timelines to provide tumor-informed, hybrid capture panels in 24 hours from panel synthesis to shipment, all while maintaining best-in-class sensitivity.

MRD Express timeline gap
Note: Performance values represent typical industry ranges for personalized MRD workflows. Turnaround Time is measured from panel synthesis to shipment. Limit of Detection (LoD95) is based on parts per million (ppm). Hybrid capture typically tracks 500–2000+ variants to achieve 0.5–5 ppm sensitivity, whereas amplicon-based methods generally track 16–64 variants with a 10–200 ppm LoD.

Secure your session

We are opening our calendar on April 7 for personalized walkthroughs. Reserve your spot now to see how MRD Express integrates with your workflow.

Schedule your walkthrough

This product is currently in development and is presented for informational purposes only. Nothing herein constitutes a commitment to deliver any described product, feature, or functionality; we reserve the right to modify or discontinue development at any time without notice. Twist products are for research use only. They are not intended for the diagnosis, prevention, monitoring, or treatment of a disease or condition. Twist Bioscience assumes no liability regarding the use of our products in unintended applications.